Alembic Pharma

₹1035 -1.3 | 0.1%

WEBSITE BSE:533573 NSE : ALEM PHARMA 26 Dec, 16:01

Market Cap ₹20344 Cr.

Stock P/E 33.0

P/B 4

Current Price ₹1035

Book Value ₹ 256

Face Value 2

52W High ₹1296.2

Dividend Yield 1.06%

52W Low ₹ 750.3

Edit Ratio

Alembic Pharma Research see more...

Overview Inc. Year: 2010Industry: Pharmaceuticals & Drugs

Alembic Pharmaceuticals Ltd is a pharmaceutical organisation. The Company is engaged developing formulations and active pharmaceutical ingredients (API). The Company specializes in analgesic, cough anti-infective, and cold therapies. It additionally focuses on cures, including gastrointestinal, orthopedic, dermatology, cardiology, diabetes, gynecology, and ophthalmology. Its APIs consist of independent production blocks for Macrolides, non-steroidal anti-inflammatory pills (NSAIDs) and different capsules. The Company gives global and home formulations. Under home components, it offers Branded Formulations and Generic formulations. Its domestic formula include Revas H, Lactonic, Folinal, Gestofit, Roxid, Zofix, Althrocin, Tellzy AH, Glisen 1/2, Glimser 1/2, Veldrop, Azithral, Brinzemic and Neolap. Its usual formulations include Alcephin, Alcizon, Baciclox, Comeba, Furobid, Cetral, Ephedrex CD, Sicor, Worid, O Win Suspension, O win T, Silomag Gel, Pentab, Aginal AT and Pyremol.

Alembic Pharma Share Price

New

Volume

Price

Price: NSE50 DMA200 DMAVolume

Quarterly Price

Quarterly Monthly

Show Value Show %

Peer Comparison

Alembic Pharma Quarterly Results

#(Fig in Cr.)
Net Sales
Other Income
Total Income
Total Expenditure
Operating Profit
Interest
Depreciation
Exceptional Income / Expenses
Profit Before Tax
Provision for Tax
Profit After Tax
Adjustments
Profit After Adjustments
Adjusted Earnings Per Share

Alembic Pharma Profit & Loss

#(Fig in Cr.)	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Net Sales	1844	2019	3009	2986	2945	3660	4133	5067	5035	5149	5874
Other Income	4	6	42	3	41	26	146	84	51	4	32
Total Income	1848	2025	3051	2989	2986	3686	4279	5151	5087	5153	5906
Total Expenditure	1485	1614	2061	2353	2347	2801	2941	3618	4127	4485	4876
Operating Profit	363	410	990	636	639	885	1338	1533	960	668	1030
Interest	10	3	4	3	2	15	25	13	17	49	54
Depreciation	40	44	72	83	102	106	136	183	285	273	271
Exceptional Income / Expenses	0	0	0	0	0	0	-10	0	0	0	0
Profit Before Tax	312	363	914	550	535	765	1167	1338	658	346	704
Provision for Tax	74	76	215	119	113	153	197	241	114	-1	38
Profit After Tax	238	287	699	431	422	611	969	1097	544	347	666
Adjustments	0	0	0	0	0	0	0	0	0	0	0
Profit After Adjustments	238	287	699	431	422	611	969	1097	544	347	666
Adjusted Earnings Per Share	12.6	15.2	37.1	22.8	22.4	32.4	51.4	55.8	27.7	17.6	33.9

Growth Rates

#	1 Year	3 Year	5 Year	10 Year
Sales CAGR	14%	5%	10%	12%
Operating Profit CAGR	54%	-12%	3%	11%
PAT CAGR	92%	-15%	2%	11%

#	1 Year	3 Year	5 Year	10 Year
Share Price CAGR	33%	10%	14%	9%
ROE Average	14%	11%	18%	28%
ROCE Average	15%	11%	17%	30%

Alembic Pharma Balance Sheet

#(Fig in Cr.)	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Shareholder's Funds	630	834	1531	1867	2195	2712	3346	5102	5290	4414	4909
Minority's Interest	0	0	0	0	0	0	0	0	0	0	0
Borrowings	52	19	0	0	500	499	887	200	0	0	0
Other Non-Current Liabilities	42	54	84	101	85	97	192	203	204	87	84
Total Current Liabilities	593	829	763	659	1012	1398	1650	1378	1694	1551	1368
Total Liabilities	1317	1735	2378	2627	3791	4706	6075	6883	7189	6052	6361
Fixed Assets	397	489	697	799	918	1077	1268	1774	1771	2377	2536
Other Non-Current Assets	96	181	160	487	1084	1636	2459	2375	2558	895	796
Total Current Assets	824	1065	1521	1341	1789	1993	2348	2734	2859	2780	3030
Total Assets	1317	1735	2378	2627	3791	4706	6075	6883	7189	6052	6361

Alembic Pharma Cash Flow

#(Fig in Cr.)	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Opening Cash & Cash Equivalents	4	5	1	281	1	9	144	36	54	14	22
Cash Flow from Operating Activities	263	180	848	327	305	809	540	1388	545	730	773
Cash Flow from Investing Activities	-111	-199	-292	-511	-794	-754	-822	-836	-369	-461	-329
Cash Flow from Financing Activities	-151	17	-276	-96	498	80	166	-534	-217	-261	-445
Net Cash Inflow / Outflow	1	-1	280	-280	9	135	-116	19	-40	8	-2
Closing Cash & Cash Equivalent	5	4	281	1	9	144	28	54	14	22	20

Alembic Pharma Ratios

#	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Earnings Per Share (Rs)	12.64	15.2	37.07	22.85	22.39	32.42	51.43	55.79	27.65	17.64	33.91
CEPS(Rs)	14.79	17.56	40.88	27.24	27.79	38.03	58.62	65.08	42.15	31.53	47.7
DPS(Rs)	3	3.5	4	4	4	5.5	10	14	10	8	11
Book NAV/Share(Rs)	33.4	44.22	81.21	99.06	116.43	143.89	177.51	259.57	269.16	224.59	249.75
Core EBITDA Margin(%)	19.36	19.9	31.49	21.18	20.32	23.48	28.84	28.6	18.05	12.9	16.99
EBIT Margin(%)	17.41	17.99	30.5	18.52	18.25	21.3	28.84	26.66	13.41	7.67	12.92
Pre Tax Margin(%)	16.85	17.84	30.38	18.41	18.17	20.89	28.23	26.4	13.07	6.72	11.99
PAT Margin (%)	12.87	14.09	23.22	14.42	14.33	16.7	23.46	21.64	10.79	6.73	11.35
Cash Profit Margin (%)	15.06	16.27	25.61	17.2	17.78	19.58	26.74	25.24	16.45	12.04	15.96
ROA(%)	19.84	18.78	33.98	17.21	13.15	14.39	17.98	16.92	7.73	5.24	10.74
ROE(%)	43.74	39.17	59.11	25.35	20.78	24.91	32	25.96	10.46	7.15	14.3
ROCE(%)	46.52	41.44	71.75	32.46	22.91	23.66	27.08	25.4	11.72	7.2	14.62
Receivable days	48.59	53.7	43.03	51.27	67.48	57.91	58.46	43.44	51.11	77.61	78.96
Inventory Days	56.93	62.2	55.57	67.74	77.12	77.85	86.76	86.99	99.26	94.7	81.66
Payable days	150.23	170.75	174.32	185.32	210.84	196.12	151.1	128.78	133.3	128.19	123.25
PER(x)	22.46	29.81	16.2	27.3	24.56	16.36	10.38	17.3	26.81	28.11	28.97
Price/Book(x)	8.5	10.25	7.4	6.3	4.72	3.69	3.01	3.72	2.75	2.21	3.93
Dividend Yield(%)	1.06	0.77	0.67	0.64	0.73	1.04	1.87	1.45	1.35	1.61	1.12
EV/Net Sales(x)	2.96	4.33	3.67	3.94	3.72	2.98	2.83	3.83	3.01	2.01	3.35
EV/Core EBITDA(x)	15.04	21.28	11.15	18.49	17.16	12.33	8.75	12.66	15.81	15.5	19.13
Net Sales Growth(%)	23.53	9.5	49.04	-0.77	-1.36	24.28	12.9	22.61	-0.62	2.26	14.08
EBIT Growth(%)	45.1	13.55	150.73	-39.75	-2.8	45.04	52.92	13.32	-50.03	-41.49	92.11
PAT Growth(%)	51.35	20.28	143.79	-38.37	-2.01	44.84	58.6	13.12	-50.43	-36.21	92.22
EPS Growth(%)	51.35	20.28	143.81	-38.37	-2.01	44.84	58.6	8.48	-50.43	-36.21	92.22
Debt/Equity(x)	0.17	0.23	0	0	0.28	0.39	0.5	0.1	0.12	0.14	0.09
Current Ratio(x)	1.39	1.28	1.99	2.04	1.77	1.43	1.42	1.98	1.69	1.79	2.21
Quick Ratio(x)	0.87	0.82	1.34	1.16	1.11	0.79	0.77	1.01	0.86	0.97	1.23
Interest Cover(x)	30.99	116.7	249.37	172.25	242.09	52.42	47.32	104.06	39.66	8.06	13.93
Total Debt/Mcap(x)	0.02	0.02	0	0	0.06	0.11	0.17	0.03	0.04	0.07	0.02

Alembic Pharma Shareholding Pattern

#	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
Promoter	69.61	69.61	69.61	69.61	69.61	69.61	69.61	69.61	69.61	69.61
FII	5.94	5.32	4.99	4.55	4.34	4.5	4.52	4.46	4.32	3.94
DII	12.15	12.54	12.76	13.31	13.64	14.22	14.5	15.39	15.47	16.05
Public	12.3	12.53	12.65	12.53	12.4	11.67	11.37	10.54	10.6	10.4
Others	0	0	0	0	0	0	0	0	0	0
Total	100	100	100	100	100	100	100	100	100	100

#	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
Promoter	13.68	13.68	13.68	13.68	13.68	13.68	13.68	13.68	13.68	13.68
FII	1.17	1.05	0.98	0.89	0.85	0.89	0.89	0.88	0.85	0.77
DII	2.39	2.47	2.51	2.62	2.68	2.79	2.85	3.02	3.04	3.15
Public	2.42	2.46	2.49	2.46	2.44	2.29	2.23	2.07	2.08	2.04
Others	0	0	0	0	0	0	0	0	0	0
Total	19.66	19.66	19.66	19.66	19.66	19.66	19.66	19.66	19.66	19.66

Pros

Debtor days have improved from 128.19 to 123.25days.
Company is almost debt free.

Cons

Company has a low return on equity of 11% over the last 3 years.
Stock is trading at 4 times its book value.
The company has delivered a poor profit growth of 1% over past five years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Alembic Pharma News

IPO

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Alembic Pharma

Add Watchlist

Alembic Pharma Research see more...

Overview Inc. Year: 2010Industry: Pharmaceuticals & Drugs

Alembic Pharma Share Price

Alert Data

Quarterly Price

Peer Comparison

Alembic Pharma Quarterly Results

Alembic Pharma Profit & Loss

Growth Rates

Alembic Pharma Balance Sheet

Alembic Pharma Cash Flow

Alembic Pharma Ratios

Alembic Pharma Shareholding Pattern

Alembic Pharma News

IPO

Stocx: India's #1 Marketplace to Find Your Winning Stock

Please Login!

Error!